We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Can Cancer Cells Be Reprogrammed Back to Normality?

By LabMedica International staff writers
Posted on 11 Nov 2008
Print article
A team of cancer researchers has published a report suggesting a novel approach to cancer therapy: instead of killing cancer cells, why not reprogram them to become normal again?

Investigators at Syracuse University (NY, USA) worked on leukemia, the form of cancer caused by the abnormal production of white blood cells in the bone marrow. They focused on the Mixed Lineage Leukemia protein-1 (MLL1), which is one of the proteins that regulate the way DNA is packaged when white blood cells are formed. MLL1 belongs to the SET1 family of histone H3 lysine 4 methyltransferases. In normal cells, the MLL protein, which contains 3,969 amino acids, combines with three other proteins, WD-repeat protein-5 (WDR5), retinoblastoma binding protein-5 (RbBP5), and the Absent small homeotic-2-like protein (Ash2L) to create a molecular switch that controls DNA packaging.

The current paper published in the October 1, 2008, online edition of the Journal of Biological Chemistry (JBC), revealed that WDR5 preferentially recognized a previously unidentified and conserved arginine containing motif called the "Win” or WDR5 interaction motif, which is located in the N-SET region of MLL1 and other SET1 family members. The Win motif comprised six amino acids and was responsible for assembling the MLL1 molecular switch in normal cells. Treatment of cells with a synthetic version of this peptide disrupted the MLL1 molecular switch and prevented white blood cell formation.

"We believe our discovery is just the tip of the iceberg,” said senior author Dr. Michael Cosgrove, assistant professor of biology at Syracuse University. "Our hope is that from the knowledge we have gained in understanding how these proteins work in normal cells, we will be able to find new ways to treat all types of leukemia. We also think the discoveries will have broad implications in treating other types of cancer.”

The investigators speculated that the MLL1 peptide might help to reprogram DNA packaging in leukemia cells and trigger the conversion of cancer cells back into normal cells. "Reprogramming the way DNA is packaged in cancerous cells is a new idea that has the potential to lead to better treatments with fewer side effects,” said Dr. Cosgrove. "This last year has been fantastic. We have been learning something new about these proteins almost on a daily basis. Our hope is that as we continue to understand how these DNA packaging proteins work, we will find new ways to treat all types of leukemia as well as other diseases.”

Related Links:
Syracuse University

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.